Canaccord analyst Kyle Rose raised his price target for Insulet to $110 from $100 and maintained a Buy rating following last week’s Q1 earnings report. In a research note to investors following the earnings report, Rose said he continues to believe Insulet is positioned favorably ahead of what he views as a compelling new product cycle in Dash.
https://thefly.com/landingPageNews.php?id=2903583
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.